Elazor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elazor

Understanding Elazor

Elazor is a pharmacological treatment classified as an antifungal medication. It belongs to the triazole class of compounds, which are specifically designed to manage and resolve infections caused by various types of fungi and yeasts.

Mechanism of Action

The active component in Elazor works by interfering with the biological processes of fungal cells. Specifically, it inhibits the synthesis of ergosterol, a vital component of the fungal cell membrane. By disrupting the integrity of this membrane, the medication prevents the fungi from growing and replicating, allowing the body's immune system to clear the infection.

Clinical Applications

Elazor is utilized in the treatment of a broad range of fungal conditions. Its systemic nature allows it to address infections in different parts of the body, including:

  • Mucosal Candidiasis: This includes fungal infections of the mouth, throat, and esophagus.
  • Systemic Fungal Infections: Internal infections affecting the bloodstream, urinary tract, or other organs.
  • Skin and Nail Infections: Various forms of tinea (such as athlete's foot or ringworm) and fungal nail conditions.
  • Cryptococcal Meningitis: A serious fungal infection affecting the membranes surrounding the brain and spinal cord.

Characteristics and Absorption

One of the defining features of this medication is its ability to penetrate various body fluids and tissues. This widespread distribution ensures that the active ingredient reaches the site of infection effectively. It is typically absorbed well by the digestive system, which allows for consistent levels of the medication to be maintained in the bloodstream during the course of treatment.

Regulatory References

  1. Fluconazole Label Information (DailyMed)

What side effects are possible with Elazor?

Adverse Reaction Scope

Side effects of Elazor (Fluconazole) are classified by regulatory authorities based on the affected System-Organ Class (SOC) and observed frequency. The most common adverse reactions, typically categorized as Common (1% and <10%), involve the Gastrointestinal System (nausea, vomiting, abdominal pain, diarrhea) and the Nervous System (headache) [SmPC, DailyMed].

Adverse events involving the skin, such as a general rash, are also documented as common. Other effects, like dizziness, dyspepsia, and transient elevations in liver enzymes, are typically classified as Uncommon (0.1% and <1%).

Serious Adverse Reactions and Safety Constraints

Rare (0.01% and <0.1%) but serious adverse reactions are documented, primarily affecting the Hepato-biliary System and Skin and Subcutaneous Tissue. These include severe hepatic toxicity (rarely leading to fatalities), Exfoliative Cutaneous Reactions (e.g., Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), and severe allergic reactions like anaphylaxis. Very Rare reports involve the Cardiac System, specifically QT interval prolongation and Torsades de Pointes, which can occur in patients with pre-existing risk factors like electrolyte imbalances [SmPC].

Population-Specific Considerations

The official safety profile contains notes for specific patient populations. The use of chronic, high-dose Fluconazole (400–800 mg/day) during the first trimester of pregnancy is associated with a rare, distinct pattern of congenital anomalies [FDA Drug Safety Communication]. The drug is also restricted in patients with diagnosed hereditary intolerances to excipients such as lactose or sucrose, which are present in certain oral formulations [DrugBank].

Connection to the Overall Safety Profile

The regulatory safety information structures the understanding of risks by categorizing expected events from rare, serious outcomes. The explicit documentation of rare cardiac and hepatic events, along with population-specific warnings and constraints, establishes the critical monitoring areas for the medicine as defined by regulatory bodies.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Elazor

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations CNS Toxicity Manifestations: Hallucination and paranoid behavior are the specific clinical signs documented in official prescribing information.
Physiological systems affected (as stated in label) Central Nervous System (CNS) and the Renal System (for drug clearance).
Management Procedures Symptomatic treatment and supportive measures should be instituted; gastric lavage may be considered. Hemodialysis is quantified: a 3-hour session decreases plasma concentrations by approximately 50%.
Population-specific overdose notes Guidance specifies seeking immediate medical advice for a child under five years old following overexposure.
When immediate medical help is required (label-derived phrasing only) Immediately call emergency services (911) if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contact a Poison Control Centre immediately.

Resulting overdose structure

Official overdose statements: • Overdose may present with CNS manifestations, specifically hallucination and paranoid behavior. • Immediate medical intervention is mandated if severe distress, such as seizure or collapse, is present. • Management involves symptomatic treatment, supportive measures, and consideration of gastric lavage. • Hemodialysis is documented as a clearance procedure, quantified at 50% reduction in plasma concentration after 3 hours.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile through specific CNS manifestations and the resultant need for immediate medical care when signs escalate to severe systemic distress. Management is officially described as supportive and symptomatic, with regulatory text detailing hemodialysis as an authorized procedure for clearance based on the drug's primary reliance on renal excretion.

Therapeutic Uses of Elazor

The medication is commonly used across three key therapeutic domains.

Therapeutic Scope and Symptom Management

The medication is applied in addressing conditions involving systemic imbalance due to invasive fungal diseases, such as those that have spread throughout the body or those affecting the central nervous system, like Cryptococcal Meningitis. It is applied in clinical settings that involve acute or unstable symptom patterns, and contributes to easing the overall symptom load to support a sense of stability during challenging symptomatic phases.

It is commonly used to help with localized yeast infections of the mouth, throat, or genital area, such as oral thrush and vaginal candidiasis. The medication is relevant for easing symptoms related to inflammatory or irritative states like soreness and burning, which provides supportive relief when symptoms interfere with routine activities, helping to improve day-to-day comfort.

Indications covered include systemic candidiasis, Cryptococcal Meningitis, and localized mucosal infections (oropharyngeal, esophageal, and vaginal candidiasis).

Prophylaxis and Recurrence Prevention

The medication is relevant for easing recurrent or episodic manifestations, and its use for prophylaxis, or prevention, is relevant in contexts involving heightened systemic burden. It is also used as long-term maintenance therapy to prevent the return of serious diseases like Cryptococcal Meningitis.

“The medication is considered relevant for easing symptoms that become more disruptive during flare-ups, and offers symptomatic relief that helps patients cope more steadily.”


Quick Fact: Relief for Mucosal Discomfort

The medication is commonly used to help manage the soreness and burning sensations that accompany localized yeast infections, which may assist with maintaining functional stability.

Regulatory References

  1. DailyMed official labeling overview

Eligibility and Restrictions for Use

Elazor (Fluconazole) eligibility is strictly defined by government regulatory documents based on patient characteristics and clinical status. The medicine is contraindicated in certain populations and requires specific caution or adjustment for others.

Absolute Contraindications (Must Not Use)

  • Patients with known hypersensitivity to fluconazole or any related azole antifungal agent.
  • Patients receiving co-administration of specific medicinal products known to prolong the QT interval and metabolized via the CYP3A4 enzyme (e.g., cisapride, pimozide, erythromycin).

Populations Requiring Conditional Use

  • Organ Function: Use requires caution in patients with liver dysfunction; patients with impaired renal function receiving multiple doses require a mandated dose reduction.
  • Physiological State: Use during pregnancy should be avoided unless necessary for life-threatening infections; high-dose regimens require effective contraceptive measures post-treatment. Breastfeeding is not recommended with repeated or high doses.
  • Age-Specific Rules: Safety is established in children ge 6 months, but term neonates (le 4 weeks) require a modified dosing frequency due to slow excretion. Use requires caution in patients with cardiac risk factors like QT prolongation.

What should I know about interactions with other medicines?

Elazor Interactions with other medicines and products

Elazor (rosuvastatin) can interact with certain other medicines, which may affect its concentration in the body or increase the risk of specific adverse effects, particularly those related to muscle health. The official regulatory documents classify interactions into categories that require monitoring, dose limitation, or specific timing requirements.

Documented Interaction Categories

Interacting Product Category Official Constraint / Requirement
Drugs Increasing Myopathy Risk Concomitant use with agents such as gemfibrozil, cyclosporine, colchicine, or certain antivirals/HIV protease inhibitors (e.g., atazanavir/ritonavir, lopinavir/ritonavir) is associated with an increased risk of muscle effects; maximum dosage limits are specified for use with these agents.
Anticoagulants Use with coumarin anticoagulants (e.g., warfarin) can significantly prolong the International Normalized Ratio (INR); the INR must be achieved and maintained at a stable level prior to starting Elazor, and frequent monitoring is required during initiation or dose changes.
Antacids Aluminum and Magnesium Hydroxide Combination Antacids decrease the absorption of Elazor. To manage this pharmacokinetic interaction, Elazor must be administered at least 2 hours after the antacid.

Mechanistic Basis and Restrictions

Many of the interactions that increase the risk of muscle effects are due to inhibition of transporter proteins such as OATP1B1 or BCRP, leading to higher-than-expected plasma concentrations of rosuvastatin. Specific restrictions apply to certain concomitant agents: use with gemfibrozil is generally avoided; if co-administration with cyclosporine is necessary, the Elazor dose must not exceed 5 mg once daily. For the oral contraceptive agents ethinyl estradiol and norgestrel, co-administration causes an increase in their systemic exposure.

Mechanism of Action

The mechanism of action for the drug Elazor (fluconazole) is centered on the selective disruption of fungal cellular integrity.

The molecule functions as a potent, non-competitive inhibitor of Lanosterol 14-alpha demethylase (CYP51), a cytochrome P450 enzyme critical to the fungal cell. By blocking this enzyme, the drug halts the conversion of lanosterol into ergosterol, the main sterol component required for the fungal cell membrane.

This enzymatic blockade initiates a dual-pronged cascade: ergosterol becomes depleted, while structurally abnormal, toxic sterols accumulate within the cell membrane. The incorporation of these faulty sterols compromises the membrane's structure, increasing its permeability and causing cellular contents to leak. This functional failure arrests the growth and reproduction of the susceptible fungal population, resulting in a fungistatic effect. This system-level physiological consequence creates a condition where host immune mechanisms can effectively engage the non-proliferating fungal cells.

Dosage and Administration Information

How to Use Elazor (Fluconazole)

The usage of Elazor is structured by defining the route, frequency, and necessary dose adjustments for proper administration. The medicine is available for both oral administration, using tablets or a liquid suspension, and intravenous (IV) administration as a sterile solution.


Dosing and Frequency Patterns

The most common frequency pattern is once daily. For specific systemic infections, the usage protocol mandates an initial loading dose—typically twice the daily maintenance dose—on the first day of treatment, followed by the standard daily dose to ensure rapid attainment of therapeutic levels. Conversely, acute vaginal candidiasis is often managed with a single 150 mg oral dose, while certain prophylactic or recurrence-prevention regimens may require a once-weekly schedule.


Contextual and Population-Specific Rules

Elazor can be taken without regard to food as its oral absorption is not significantly affected by meals. For patients requiring the intravenous solution, the administration rate is crucial and must not exceed 10 mL/minute.

Specific dosage modifications are required for certain patient groups. Dosing for pediatric patients is based on body weight (mg/kg). Furthermore, patients with compromised renal function must have their dose reduced, typically by 50% for the maintenance phase if their creatinine clearance is less than or equal to 50 mL/min.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elazor (Fluconazole)

The research landscape for Elazor includes studies derived primarily from Randomized Controlled Trials (RCTs) and systematic reviews documented in governmental and peer-reviewed literature. These studies primarily focus on measuring mycological outcomes (clearance of fungal organisms) and clinical symptom patterns across specific patient groups.


Evidence for Systemic Candidiasis

Comparative RCTs have explored the administration of Elazor for systemic fungal infections, such as Candidemia, often in hospitalized and critically ill adults. Researchers examined the rate at which the fungal organism was measured (mycological outcomes) and overall patient survival, often comparing findings to other antifungal agents. Evidence consistency is subject to continuous monitoring due to documented patterns of antifungal resistance that may emerge in certain Candida species over time.


Evidence for Cryptococcal Meningitis

Research has explored the administration of Elazor in studies of this serious central nervous system infection. Trials evaluated its role in both initial (induction) therapy and long-term maintenance therapy designed to prevent recurrence. Studies primarily focused on the measured fungal clearance rate in the Cerebrospinal Fluid (CSF) in immunocompromised adults. Findings described that using Elazor alone for initial treatment may be associated with lower clearance rates compared to multi-drug regimens.


Evidence for Localized Mucosal Infections

Research examined the administration of Elazor for common localized infections (e.g., oral thrush and vaginal candidiasis) using short-term RCTs. Studies monitored changes in symptoms (such as soreness or burning) and mycological outcomes, as well as tracking recurrence rates. Long-term recurrence data for chronic, non-immunocompromised presentations remains limited.


Special Populations and Research Gaps

Studies included cohorts of Very Low Birth Weight (VLBW) preterm infants, where the incidence of Invasive Fungal Infection (IFI) was evaluated relative to control groups. Research in other immunocompromised adults focused on patterns observed during treatment and maintenance. A key research limitation is the ongoing concern regarding the emergence of antifungal resistance following prior use of antifungal agents, and the fact that long-term effects are not fully established for all functional outcomes.

Key Studies & References

  1. Label: FLUCONAZOLE tablet - DailyMed (NIH)
  2. Study Details | NCT00885703 | High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals (ACTG A5225)

Frequently Asked Questions (FAQ)

Common questions about Elazor (FAQ)


Q: Can Elazor be used for conditions other than its main approval?

A: Elazor is approved by regulatory bodies to treat and prevent specific fungal infections caused by susceptible organisms. Official regulatory documents indicate that the use of this medicine is limited to those specific conditions for which it has been formally approved.

Q: Are there studies about Elazor and pregnancy?

A: Yes, studies inform the official warnings for this medicine. Regulatory documents indicate that the use of high, chronic doses during the first trimester of pregnancy has been associated with a rare, distinct pattern of congenital anomalies. Use during pregnancy is generally avoided unless necessary for life-threatening conditions.

Q: What does the term 'contraindication' mean for Elazor?

A: A contraindication is a regulatory term meaning the drug should not be used under any circumstances. Official information states this is typically due to a specific pre-existing condition, such as a known allergy, or co-administration with certain other medicines that pose a serious risk.

Q: Why do some people stop using Elazor?

A: Treatment cessation, as documented in regulatory summaries, occurs for a few reasons. The most common is the resolution of the infection being treated. Other factors include the occurrence of adverse side effects or evidence of treatment failure, such as the development of antifungal resistance in the organism.

Q: What is the mechanism of action of Elazor in simple terms?

A: Elazor works by preventing the fungal organism from manufacturing a critical substance called ergosterol. Ergosterol is essential for building and maintaining the fungal cell's protective outer wall. By disrupting this vital process, the medicine stops the fungal cell from growing and multiplying, which is its fungistatic activity.

Q: How long is the typical course of treatment with Elazor?

A: The duration of treatment is highly variable according to the specific infection being addressed. Official prescribing documents show courses can range from a single oral dose for acute conditions to several weeks or months for more serious cases. In some instances, it is used indefinitely as long-term preventative maintenance therapy.

Q: How long does it typically take to notice the effects of Elazor?

A: According to regulatory data, the time until effects are noticed depends on the condition. For simple, localized infections, symptom relief can often begin within 24 hours of administration. For more severe or deep-seated systemic infections, it may take several days or weeks of treatment before an improvement is observed.

Q: Can older adults use Elazor?

A: Yes, Elazor is generally used in older adults, and its use is established in this population. Official guidelines indicate that a dose adjustment is often required for the maintenance phase of treatment if the patient has any reduction in kidney function, a factor that is commonly monitored with age.

Q: Are there any known issues with drinking alcohol while using Elazor?

A: Official guidance advises caution regarding the combined use of Elazor and alcohol. Regulatory documents note that Elazor, like alcohol, can stress the liver, and combining the two may increase the documented risk of serious adverse effects, including potential liver damage, especially with chronic administration.

Q: What happens if I miss a dose of Elazor?

A: Official patient information contains specific instructions for handling a missed dose, typically advising against taking two doses together. These instructions should be reviewed carefully with your pharmacist or prescribing doctor.

Q: Is Elazor a controlled substance?

A: No, Elazor, which contains the active ingredient Fluconazole, is not classified as a controlled substance. Official sources indicate that it is a prescription-only medicine (Rx) but is not placed on the schedules maintained by the U.S. Drug Enforcement Administration (DEA).

Q: Can I take Elazor with my daily vitamins or supplements?

A: Official drug interaction information focuses on major drug classes and does not typically specify interactions with general vitamins or over-the-counter supplements. Healthcare professionals generally recommend that patients inform their prescribing doctor about all products taken, including supplements, to assess potential risks.

Q: Is it common to feel tired when starting Elazor?

A: Studies have documented that some patients have reported feeling tired (fatigue) or a general feeling of malaise as an adverse reaction. If this feeling persists or becomes bothersome during treatment, it should be brought to the attention of the prescribing healthcare provider.

Q: How does Elazor affect sleep patterns?

A: Adverse reactions listed in regulatory documents include effects on the nervous system. Specifically, there have been reports of insomnia, which is difficulty sleeping, and somnolence, which is drowsiness or feeling sleepy.

Q: Does Elazor interact with blood pressure medications?

A: Yes, official interaction documents indicate that Elazor can interact with certain types of blood pressure medicines, specifically Dihydropyridine Calcium Channel Blockers. This interaction may result in higher blood levels of the blood pressure medicine. The need for careful monitoring and potential dose adjustment is noted in official regulatory guidance due to this interaction.

Q: Are there generic versions of Elazor available?

A: Yes, the active ingredient in Elazor is Fluconazole, and generic versions of Fluconazole are widely approved and available. Generic medicines are required by regulatory bodies to contain the identical active ingredient, strength, and dosage form as the brand name, meeting the same standards for quality and effectiveness.

Q: What should I do if the side effects of Elazor become bothersome?

A: Official patient guidance typically includes a statement on reporting bothersome side effects to the prescribing healthcare provider. It is noted in patient information that treatment should not be stopped or adjusted without consulting a medical professional.

Q: Does Elazor affect hormone levels?

A: Official drug information indicates that Elazor can affect the metabolism of certain hormonal medicines, such as increasing the systemic exposure of oral contraceptives. However, regulatory summaries generally report that the drug does not cause significant or clinically relevant changes to overall hormone levels in most patients.

Q: Is it possible to develop a dependency on Elazor?

A: No. The medicine is not classified as a controlled substance by regulatory bodies, and there is no evidence that patients develop physical or psychological dependency on the medicine.

Q: Have there been any major updates to the safety information for Elazor recently?

A: Safety information is continuously reviewed by regulatory bodies like the FDA and EMA. Official changes are published when new data warrants a review of the safety profile. For example, a Drug Safety Communication was issued to address the risk of congenital anomalies associated with high, chronic doses during early pregnancy.

Q: Does taking Elazor affect the results of any common medical tests?

A: Regulatory documents indicate that Elazor can cause transient, mild elevations in liver enzyme levels, which may affect the results of liver function tests. Furthermore, rare adverse reports mention changes in blood cell counts, such as leukopenia or thrombocytopenia, which are typically monitored.

Q: Are the effects of Elazor permanent after stopping treatment?

A: The effects of Elazor are not permanent. The drug functions by suppressing the growth of the fungal organism. Therefore, stopping treatment prematurely may lead to the recurrence of the fungal infection, which is why maintenance therapy is necessary for certain long-term conditions.

Q: Does Elazor interact with pain relievers like ibuprofen?

A: Official regulatory documents do not list a major interaction or contraindication between Elazor and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Healthcare professionals typically advise informing the prescribing doctor about all medicines and products being taken.

Q: What is the difference between the brand name and generic Elazor?

A: The only difference between the brand name and the generic version (Fluconazole) is the name and the manufacturer. Regulatory bodies require that the generic version contains the identical active ingredient, strength, and dosage form as the brand name, meaning they are equally effective.

Q: Can Elazor be crushed or split?

A: The official product label for the tablets does not contain specific instructions regarding crushing or splitting them. The official product labeling indicates that if swallowing difficulties exist, consultation with a pharmacist or prescriber is appropriate, as an oral suspension (liquid) formulation is available.

Q: Is there a maximum time Elazor should be used?

A: There is no single, fixed maximum time limit for all uses. The duration of treatment is determined entirely by the type and severity of the infection. Treatment can range from a single dose for acute issues to long-term preventative maintenance therapies that may last indefinitely.

Q: What happens when treatment with Elazor is stopped?

A: Official safety information notes that treatment cessation is typically managed under the guidance of a healthcare professional. Official information indicates that stopping the medicine too early for infections that require long-term suppression can lead to a rapid recurrence of the fungal infection that the medicine was intended to prevent.

How should Elazor be stored and disposed of?

How to Store and Dispose of Elazor (Fluconazole)

Official Storage Conditions

Elazor tablets and dry powder must be stored at or below 30°C (86°F) and protected from direct sunlight. All forms of the medication must be kept in a tightly closed container and maintained out of the sight and reach of children. The reconstituted oral suspension and the injection solution must not be frozen.

Stability and Disposal Rules

Dosage Form Stability Limit Disposal Method
Reconstituted Oral Suspension Discard after 14 days Follow official FDA guidelines
Tablets/Injection Until Expiration Date Follow official FDA guidelines

Disposal must adhere to federal guidelines, often recommending drug take-back programs or household disposal by mixing with an undesirable substance. The product must not be flushed down the toilet or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elazor found in:

A-Z Index: